Can reduction of uncertainties in cervix cancer brachytherapy potentially improve clinical outcome?

TCP is robust to dosimetric uncertainties when dose prescription is in the more flat region of the dose-response curve at doses >75 Gy. For OARs, improved clinical outcome is expected by reduction of uncertainties via sophisticated dose delivery and treatment verification.